| The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia. | |
| | |
MedLine Citation:
|
PMID: 15238825 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Atorvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, which is used for lipid-lowering therapy, is an effective statin modulating process involved in atherosclerosis. Paraoxonase (PON) associated with high-density lipoprotein (HDL) has been postulated to have a role in protecting low-density lipoprotein (LDL) against oxidative modification. Oxidation of serum LDL is an important early step in the development of atherosclerosis and auto-antibodies against oxidized LDL (AuAb-oxLDL) reflect in-vivo LDL oxidation. DESIGN AND METHODS: To examine the effect of atorvastatin (10 mg/day) therapy on PON activity in serum and HDL, the study group included 40 patients with dyslipidemia (19 women and 21 men), 25 of whom had hypercholesterolemia and of 15 of whom had mixed-type hyperlipidemia. By taking blood samples from the patients, levels of serum lipids, lipid peroxidation product as malondialdehyde (MDA), total antioxidant status (TAS) and AuAb-oxLDL and the activities of PON in serum and isolated HDL were determined. RESULTS: The mean levels of total cholesterol, triglyceride, LDL-cholesterol, MDA and AuAb-oxLDL were decreased while HDL-cholesterol and TAS were increased significantly after lipid-lowering therapy in patients with dyslipidemia. On the other hand, PON activities in serum and HDL were increased significantly. The percentage increase in serum PON activity was associated significantly with the percentage decrease in serum AuAb-oxLDL (r=-0.32, P=0.047) and that of HDL PON activity was associated with the percentage increase in HDL-cholesterol level after atorvastatin therapy (r=0.52, P=0.001). The therapy was more effective in increasing PON activity in patients with HDL levels above 35 mg/dl. CONCLUSION: It was concluded that atorvastatin therapy in dyslipidemic patients decreases the level of oxidative stress and increases PON activity, especially in patients with HDL levels above 35mg/dl. |
| | |
Authors:
|
Birgül Vanizor Kural; Cihan Orem; Hüseyin A Uydu; Ahmet Alver; Asim Orem |
Related Documents
:
|
15317825 - Possible induction of cholinesterase in epileptic patients treated with anticonvulsant ... 19858435 - Evaluating the incremental benefits of raising high-density lipoprotein cholesterol lev... 19320405 - Prevalence of dyslipidaemia in apparently healthy professionals in asaba, south south n... 9781625 - Effects of oral combined hormone replacement therapy on plasma lipids and lipoproteins. 10441245 - Binge eating severity, self-concept, dieting self-efficacy and social support during tr... 12033835 - Antioxidative functions of natto, a kind of fermented soybeans: effect on ldl oxidation... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Coronary artery disease Volume: 15 ISSN: 0954-6928 ISO Abbreviation: Coron. Artery Dis. Publication Date: 2004 Aug |
Date Detail:
|
Created Date: 2004-07-07 Completed Date: 2006-03-17 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9011445 Medline TA: Coron Artery Dis Country: England |
Other Details:
|
Languages: eng Pagination: 277-83 Citation Subset: IM |
Affiliation:
|
Department of Biochemistry, Karadeniz Technical University, Trabzon, Turkey. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Anticholesteremic Agents / therapeutic use* Antioxidants / metabolism* Aryldialkylphosphatase / metabolism* Biological Markers / blood Cholesterol, HDL / metabolism Cholesterol, LDL / metabolism Dyslipidemias / drug therapy*, metabolism* Female Heptanoic Acids / therapeutic use* Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use* Lipoproteins, LDL / metabolism Male Middle Aged Pyrroles / therapeutic use* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Antioxidants; 0/Biological Markers; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Lipoproteins, LDL; 0/Pyrroles; 0/oxidized low density lipoprotein; 110862-48-1/atorvastatin; EC 3.1.8.1/Aryldialkylphosphatase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Does resting two-dimensional echocardiography identify patients with ischemic cardiomyopathy and low...
Next Document: Intracoronary brachytherapy with beta-radiation for the treatment of long diffuse in-stent restenosi...